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Live donor kidney transplantation has become a widely sought
treatment by patients with end-stage renal failure. As the
outcome for the genetically and emotionally related live donor
transplants is the same, this review considers live kidney
transplantation from the broad scope of current international
practice. Unrelated live donor transplantation can now be
performed for incompatible donor recipient pairs via a
simultaneous paired kidney donation. However, acceptance of
the scientific data that an unrelated live donor transplant can
now be performed successfully should not be misconstrued as
an acceptance that an unrelated kidney may be purchased via
a vendor sale. At a recent World Health Organization (WHO)
conference of Middle East transplant professionals a statement
of unequivocal opposition to commercialism was drafted. In
the United States, the Institute of Medicine has recently
published a significant report that affirms the legal prohibition
of organ sales. These documents are in accord with the
guiding principles of the WHO and the membership policy of
The Transplantation Society. The person who gives consent to
be a donor should be competent, willing to donate, free of
coercion, medically and psychosocially suitable, and fully
informed of the risks and benefits as a donor. With these
principles established, the Amsterdam Forum has set forth a
comprehensive list of medical criteria that is now used
internationally in the evaluation of potential kidney donors.
Guidelines of a psychosocial evaluation are also presented in
this report for individuals who come forward through internet
solicitation and other public appeals. It is now evident that the
annual number of available deceased donors will not resolve
the ongoing shortage of organs. Nevertheless, live donor
kidney transplantation may not be the realistic final solution to
an international public health epidemic of renal failure that is
the result of an aging population of patients that have had
inadequate preventive medical care.
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Live donor kidney transplantation is emerging as the
predominant practice of kidney transplantation around the
world. The scientific, cultural, and economic forces that are
leading to this development have been independently driven
but the effect from each factor has been to propel live donor
transplantation as a common resolve for patients in need of a
kidney transplant. This development was anticipated by the
pioneers of transplantation; Dr Francis Moore noted 40 years
ago, that the live donor kidney would provide ‘the best tissue’.
Today, the live donor does indeed afford the recipient the best
opportunity for successful transplantation.1
The ethical underpinnings of live donor kidney trans-
plantation are not only built upon its widely reported success
but by a recognition of minimal risk to be a living kidney
donor. The survival of a kidney transplanted from a live
donor exceeds the results achieved from a deceased donor.2
Furthermore, this success of live donor transplantation no
longer necessitates the consideration of an human leukocyte
antigen (HLA) match unless there is the relatively uncom-
mon possibility of a kidney transplant from HLA identical
sibling.3 The survival rate of a kidney transplant from a
genetically unrelated donor is excellent, with a 10-year
survival equivalent to a kidney transplant from a sibling HLA
haploidentical to the recipient.4 This information is now well
known by patients who might otherwise have gone on a
waiting list for a deceased organ. Patients have thus appealed
for kidneys from living donors who have no HLA identity.
Thus, the transplantation of a kidney from a living donor
has evolved in the past 50 years from the limitation of
requiring an identical twin (in 1954), to the selection of an
HLA-matched family member (during the 1980’s), to the
current reality that any person (irrespective of the HLA
match) can be a donor if they are medically and
psychosocially suitable. Spouses, friends, and most recently
individuals unknown to the recipient, have become a donor
source for patients in need of a kidney transplant. The term
‘living related’ donor has been defined as having at least some
HLA identity with the recipient, but emotional bonds forged
in marriage or friendship are just as credible in defining a
donor as ‘related’ to the recipient. As the outcome for the
genetically and emotionally related transplants are the same,
the remainder of this review will consider the live kidney
donor from a broad scope of the current practice live donor
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transplantation as either genetically or emotionally ‘related’.
The review will also consider the expansion of current
practice to include ‘unrelated’ live donors, namely indivi-
duals who have neither a genetic nor longstanding emotional
relationship to the transplant recipient.
Aside from medical and scientific developments, the
practice of living donor kidney transplantation has also been
propelled by cultural and economic forces. There is a cultural
objection at this time to deceased donation in certain regions
of the world, for example, in the Middle East and Asia.5,6 In
some developing countries in Africa or Central America,
living donor transplantation programs have been initiated
before kidney transplantation from deceased donors was
established. The resources necessary to develop an organized
system of deceased donation are limited in developing
countries and the legal framework for the determination of
brain death in an intensive care environment may not be
currently feasible.
Certainly there are international models that are fostering
deceased donation. The commendable work of the Organiza-
cion Nacional de Trasplantes (ONT), the Collaborative of the
Department of Health and Human Services in the United
States and Iberboamericana de Donation y Trasplantes of
Central and South America are examples. These efforts have
been championed by the World Health Organization (WHO)
in regional consultations in Manila, Karachi, and Ljubljana
and most recently at the Buenos Aires 2006 World Donation
Day. The WHO has maintained the Guiding Principles on
Transplantation adopted by the World Health Assembly
(WHA) in 1991 that deceased donation should be used to its
maximal therapeutic potential.7 The sensible rationale for
this direction is that kidney transplantation from a deceased
donor does not place a living person at risk for untoward life-
long complications.8 As is now evident by the Amsterdam
Forum, live donor transplantation has been safely performed
for the past 50 years; but a changing profile of medical
suitability is increasing the hazard of live organ donation.9
Individuals who have been live donors have subsequently
developed kidney failure from 5 to 15 years after donation
and find themselves in need of a kidney transplant.10
PRINCIPLES OF LIVE KIDNEY DONATION
A fundamental set of principles has been established by the
transplant community for the live organ donor. The person
who gives consent to be a donor should be competent, willing
to donate, free of coercion, medically and psychosocially
suitable, fully informed of the risks and benefits as a donor,
and fully informed of risks, benefits, and alternative
treatment available to recipient. The benefits to both donor
and recipient must outweigh the risks associated with the
donation and transplantation of the living donor organ.11
Before donation, the live kidney donor must receive a
complete medical and psychosocial evaluation, undergo an
appropriate informed consent process, and be capable of
understanding the information presented in that process to
make a voluntary decision.12
At all stages of the evaluation and transplantation process,
the donor is as legitimately considered to be a patient as the
transplant recipient and thus should be afforded the same
level of care and the same protections against undue risks.13
MEDICAL SUITABILITY
With these principles established, the Amsterdam Forum set
forth a comprehensive list of medical criteria that is now used
internationally in the evaluation of potential kidney donors
(Table 1).9 All donors should have standard tests performed
to assure donor safety that address the risk of immediate and
long-term negative health consequences for the live donor.
PSYCHOSOCIAL SUITABILITY AND WILLINGNESS TO DONATE
It is now well accepted that every living organ donor should
undergo a psychosocial evaluation. The process of conduct-
ing this evaluation may consist of a brief initial screening of
the potential donor conducted via telephone or by an initial
visit to the transplant center. The purpose of the screening
assessment is to obtain basic information regarding the
individual’s motives for donation, current psychosocial status
(for example employment status, family support resources
during the operative recovery period, and general psycholo-
gical well-being), and a knowledge of basic facts about the
risks involved in donation. Unless there is an overriding
contraindication to donation, the transplant program would
refer the prospective donor to the second stage of the
evaluation process, ideally by a team of care providers whose
focus and interest is on the well-being of the potential donor
and not on the recipient. The second stage consists of a face-
to-face assessment covering the components in Table 2.
Depending on results of this face-to-face assessment, the
prospective donor may be referred for additional psycho-
logical evaluation. For example, an individual who is
currently psychologically healthy but who has a history of
psychiatric disorder (e.g., major depression) may require
additional evaluation in order to determine whether he or
she is at a heightened risk of recurrence of psychiatric illness
as a result of donation.
The major psychosocial contraindications for live dona-
tion would include (a) ongoing psychiatric or substance use
problems, (b) the presence of major financial stressors that
could either have a coercive effect on the donor’s decision to
donate, or significantly worsen as a result of donation and
any medical complications, (c) evidence that the prospective
donor has experienced undue pressure or coercion from
others to donate, (d) a limited understanding or capacity to
understand the donor’s own or the transplant candidate’s
risks and benefits from kidney donation, and (e) ambivalence
about proceeding with the donation.
A GLOBAL TRANSPLANT TOURISM
The ongoing disparity between the demand and supply of
organs for transplantation is now at the attention of the
international transplant community. The intersect of patients
in desperate need with transplant centers whose intent is to
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Table 1 | Amsterdam forum guidelines
Acceptable donor renal function
All potential kidney donors should have GFR estimated.
Creatinine-based methods may be used to estimate the GFR; however, creatinine clearance
(as calculated from 24-h urine collections) may under or overestimate GFR in patients with normal or near normal renal function.
Calculated GFR values (MDRD and Cockcroft-Gault) are not standardized in this population and may overestimate GFR.
A GFRo80 ml/min or 2 s.d. below normal (based on age, gender, and BSA corrected to 1.73 per m2) generally preclude donation.
Hypertension
Patients with a BP4140/90 by ABPM are generally not acceptable as donors.
BP should preferably be measured by ABPM, particularly among older donors (450 years) and/or those with high office BP reading.
Some patients with easily controlled hypertension, who meet other defined criteria, e.g. 450 years of age, GFR 480 ml/min, and urinary albumin
excretiono30 mg/day may represent a low-risk group for development of kidney disease after donation and may be acceptable as kidney donors.
Donors with hypertension should be regularly followed by a physician.
Obesity
Patients with a BMI435 kg/m2 should be discouraged from donating, especially when other comorbid conditions are present.
Obese patients should be encouraged to lose weight before kidney donation and should be advised not to donate if they have other associated
comorbid conditions.
Obese patients should be informed of both acute and long-term risks, especially when other comorbid conditions are present.
Healthy lifestyle education should be available to all living donors.
Dyslipidemia
Dyslipidemia should be included along with other risk factors in donor risk assessment, but dyslipidemia alone does not exclude kidney donation.
Urine analysis for protein
A 24 h urine protein of 4300 mg is a contraindication to donation.
Microalbuminuria determination may be a more reliable marker of renal disease but its value as an international standard of evaluation for kidney
donors has not been determined.
Urine analysis for blood
Patients with persistent microscopic hematuria should not be considered for kidney donation unless urine cytology and a complete urologic work up
are performed. If urological malignancy and stone disease are excluded, a kidney biopsy may be indicated to rule out glomerular pathology such as
IgA nephropathy.
Diabetes
Individuals with a history of diabetes or fasting blood glucoseX126 mg/dl (7.0 mmol/l) on at least two occasions (or 2 h glucose with OGTTX200 mg/
dl (11.1 mmol/l) should not donate.
Stone disease
An asymptomatic potential donor with history of a single stone may be suitable for kidney donation if:
No hypercalcuria, hyperuricemia, or metabolic acidosis.
No cystinuria or hyperoxaluria.
No urinary tract infection.
If multiple stones or nephrocalcinosis are not evident on CT.
An asymptomatic potential donor with a current single stone may be suitable if:
The donor meets the criteria shown previously for single stone formers and current stone o1.5 cm in size, or potentially removable during the
transplant.
Stone formers who should not donate are those with:
(a) Nephrocalcinosis on X ray or bilateral stone disease and
(b) Stone types with high recurrence rates, and are difficult to prevent (see text).
Malignancy
A prior history of the following malignancies usually excludes live kidney donation:
Melanoma, testicular cancer, renal cell carcinoma, choriocarcinoma, hematological malignancy, bronchial cancer, breast cancer, and monoclonal
gammopathy.
A prior history of malignancy may only be acceptable for donation if:
Prior treatment of the malignancy does not decrease renal reserve or place the donor at increased risk for ESRD.
Prior treatment of malignancy does not increase the operative risk of nephrectomy.
A prior history of malignancy usually excludes live kidney donation but may be acceptable if.
The specific cancer is curable and potential transmission of cancer can reasonably be excluded.
Urinary tract infections
The donor urine should be sterile before donation; asymptomatic bacteruria should be treated pre donation.
Pyuria and hematuria at the proposed time of donation is a contraindication to donation.
Unexplained hematuria or pyuria necessitates evaluation for adenovirus, tuberculosis, and cancer. Urinary tuberculosis or cancer are contraindications
to donation.
Table 1 continued on the following page
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attract patients from around the world has set into motion a
‘transplant tourism’ that may bypass existing law, rules, or
ethical processes in the countries involved. Brokers of
transplant tourism exploit vendors of kidney sales (and their
recipients) whose only motivation is monetary gain by the
transaction of the kidney sale. These situations are now well
known by clinical experience to be conducted with
inadequate evaluation and care for the kidney vendor.
Meanwhile, the recipients are exploited, vulnerable to the
transmission of infectious diseases such as tuberculosis or
hepatitis from inadequately evaluated vendors.
A regional meeting of the Pan American Health
Organization was recently held in Port of Spain, Trinidad
to develop a national framework of practice in the Caribbean
Islands propelled in part by the experience of a ranking
government official from Trinidad/Tobago who had traveled
to Pakistan to purchase a kidney and died soon thereafter
from medical complications. Many transplant professionals
can relate an anecdotal experience of patients who have gone
to Pakistan, Egypt, China, or South America to purchase an
organ, only to have that patient to return to their home
country with a complicated course.
Table 1 | Continued
Acceptable donor renal function
Live unrelated donors
The current available data suggest no restriction of live kidney donation based upon the absence of an HLA match. An unrelated donor transplant is
equally successful to the outcome achieved by a genetically related family member such as a parent, child, or sibling, who is not HLA identical to the
recipient.
Determination of cardiovascular risk
The clinical predictors of an increased perioperative cardiovascular risk (for non-cardiac surgery) by the American College of Cardiology /American
Hospital Association standards fall into three categories: major, intermediate, and minor.
All major predictors: unstable coronary syndromes, decompensated heart failure, significant arrhythmias and severe valvular disease are
contraindications to live kidney donation. Most of the intermediate predictors: mild angina, previous myocardial infarction, compensated or prior
heart failure, and diabetes mellitus are also contraindications to donation. Minor predictors: older age, abnormal ECG, rhythm other than sinus, low
cardiac functional capacity, history of stroke, or uncontrolled hypertension warrant individual consideration.
Assessment of pulmonary issues
A careful history and physical examination are the most important parts of assessing risk. Routine preoperative PFT is not warranted for potential live
kidney donors unless there is an associated risk factor such as chronic lung disease. Increased risk of post operative pulmonary complication is assoc
with an FEV1o70% or FVCo70% of predicted, or a ratio of FEV1/FVCo65%.
Smoking cessation and alcohol abstinence
Smoking cessation at least 4 weeks before donation is advised based on recommendations for patients undergoing elective surgical procedures.
Cessation of alcohol abuse defined by DSM-3: 60 gm of alcohol/day sustained over X6 months should be avoided for a minimum of 4 weeks to
decrease the known risk of postoperative morbidity.
ABPM, ambulatory blood pressure monitoring; BMI, body mass index; BP, blood pressure; BSA, body surface area; CT, computed tomography; DSM, Diagnostic and Statistical
Manual of Mental Disorder; ECG, electrocardiography; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HLA, human leukocyte antigen; Ig, immunoglobulin;
OGTT, oral glucose tolerance test; PFT, pulmonary function testing; s.d., standard deviation.
Table 2 | Components of the psychosocial evaluation of living kidney donors
Component Description of content
Sociodemographic history and
current status
Educational attainment, living situation, religious beliefs and practices, marital status, and employment.
Capacity Cognitive status and capacity to comprehend information; risk for exploitation by others for monetary or other
personal gain.
Psychological status Presence of current and past psychiatric disorder, including mood, anxiety, substance use, personality or other
serious disorders. Current and past use of therapeutic interventions (counseling and medications) for psychological
or other stressors including sexual abuse, or for chronic pain management. Nature of coping skills to manage
current or past life or health-related stressors.
Relationship with transplant
candidate
Nature and degree of relationship (if any) to transplant candidate; whether donation would impose expectations or
perceived obligations.
Motivation Rationale and reasons for volunteering to donate; perceived coercion or undue pressure by others to donate.
Knowledge, understanding, and
preparing for donation
Awareness of short- and long-term risks for surgical complications and health outcomes; understanding of recovery
and recuperation time; availability of alternative treatments for the transplant candidate.
Social supports Spouse or other significant family members’ support for proceeding with donation; support from other sources
(friends and employer).
Financial status and suitability Financial stability and freedom from current or expected financial hardship; availability of resources to cover
expected and unexpected donation-related expenses; availability of disability and health insurance.
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Nevertheless, progress is seemingly being made to expose
unacceptable practices and equip health authorities with legal
means to assume their responsibilities such as in Pakistan. At
a recent ceremony for live donors in Karachi, President
Musharaaf wrote in a letter to participants that ‘legislations
would soon be in place to discourage illegal trade in human
organs’. In China, where transplant tourism has been very
active, the Central Government is now taking legal measures
to put a stop to this activity. Other countries such as the
Philippines are developing quotas of acceptable foreign
national candidates to curtail transplant tourism.
For the live kidney donor, the process of informed consent
and the determination of medical suitability have now been
comprehensively established by the Amsterdam Forum.
Reflection on the optimal organization and practices in
kidney transplantation is now very timely to promote the
concept of transparency, equitable respect for the person of
the recipient and of the live organ donor and to maximize
transplantation from deceased donors.
BUYING AND SELLING OF ORGANS
The WHO and The Transplantation Society are opposed
to the buying and selling of organs.14 The human body
and its parts should only be freely donated. Financial profit
for the donor or family is prohibited, but these stipulations
do not – and should not – prevent compensation for
justifiable expenditures associated with the donation which
could act as disincentives including loss of earnings for the
live donor.
Regulated markets for organ sales now exist, most notably
in Iran.15 The Iranian model has been touted internationally
as a solution to the increasing demand for organs. It disavows
transplant tourism but it does not achieve an ethical
propriety as the payments are not solely from government
sources and they are not fixed. At least 85% of the vendors
are destitute, increasing the risk that the potential donor will
withhold relevant medical information and not be followed
after nephrectomy.16 Altruistic donation has disappeared.
Moreover, the psychological consequences of organ vending
in Iran are profoundly negative for the donor.17 At a recent
WHO conference in Kuwait, of Middle East transplant
professionals from the Gulf Countries, from Lebanon, Syria,
Jordan, and more a statement was drafted of unequivocal
opposition to commercialism in the region.
In the United States, the Institute of Medicine has recently
published a significant report that affirms the legal opposi-
tion to organ sales and notes that ‘Every society draws lines
and separating things that are created as commodities from
things that should not be treated as ‘for sale’.18 The
committee believes that there are powerful reasons to
preserve the idea that organs are donated rather than sold
even in a regulated market’.
Despite the writings of some American transplant
professionals to the contrary, there is no consideration by
the US Congress to change the 1984 National Organ
Transplant Act that prohibits any person ‘to knowingly
acquire, receive, or otherwise transfer any human organ for
valuable consideration for use in human transplantation’.19
NON-DIRECTED LIVING KIDNEY DONATION
As mentioned previously, in some instances individuals are
coming forward to altruistically donate a kidney to someone
in need but unknown by the potential donor.20 The non-
directed donor volunteers to donate an organ for a recipient
that he or she does not know or select and may never meet.
The recipient, in effect, is a ‘stranger’. Thus, media reports
and some potential donors have used the term ‘Good
Samaritan Donor’ to convey the novel concept and charity of
non-directed donation.
Alternatively, a directed organ donor is a genetically
related family member (i.e., sibling and parent), has a
longstanding emotional relationship with the transplant
recipient, or has formed a connection with the patient as a
result of the patient’s need for a transplant.
Less commonly, a directed donor may know of a
particular transplant candidate in need of a donated organ
and only develop a relationship with that recipient for the
purpose of the transplant (e.g., church members, response to
public, or media notice). These donors have been accepted if
medically and psychosocially suitable.
Some countries in Europe and South America will not
currently allow this practice because they are apprehensive
that the unrelated non-directed donor may be selling an
organ.21 Country law requires living donors to be first or
second degree relatives of recipients or have close emotional
ties with them. This condition and the absence of any
financial interest for donation are evaluated by an ethical
board. The Ethics Board in Hong Kong determines if the
donor is not genetically related to the recipient (i.e., friends
and in-laws), is a spouse of 3 years, or if the donor is
genetically related but without proof of official documents
(i.e., birth certificate or marriage certificate) to establish that
relationship.21
PAIRED EXCHANGE DONATION
Non-directed donation can be exercised in another more
recent and novel approach to live donor transplantation via
simultaneous paired kidney donation.22–25 For those who
have a willing but incompatible donor by blood type and
crossmatch reactivity, the concept of paired kidney donation
was first proposed by Rapaport in 1986.26 However, this
approach was not considered more extensively until sample
data confirmed that the absence of an HLA match of the
donor recipient pair would not be detrimental to outcome.27
Today centers may develop policies for paired and three-way
donation when incompatible donor/recipient pairs are
identified. The Figure 1 illustrates a three-way exchange
recently accomplished in New England.28
The New England program also has a variation on this
approach by performing a live donor list exchange. If there is
no opportunity for a live donor paired exchange, the
incompatible living donor may provide a kidney to a patient
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on the transplant center’s deceased donor waiting list in
exchange for a kidney allocated from the deceased donor
pool to the incompatible recipient of the live donor.29
INTERNET SOLICITATION
The Internet web site matching donors. com, was established
to help candidates for kidney transplantation identify
potential organ donors.30 Internet relationships now develop
through correspondence that is not limited to transplanta-
tion. Public solicitation of live donor organs cannot be
regulated or restricted as long as no felonious or illegal
activity is involved (for example in the United States, no
party knowingly acquires, receives, or otherwise transfers any
human organ for valuable consideration for use in human
transplantation). In other words, the ways in which relation-
ships are developed in society with respect to live organ
donation cannot be regulated or restricted.31
A recent UNOS-sponsored conference in the United States
focused on the development of guidelines for the psychoso-
cial evaluation of living donors who come forward through
internet solicitation and other public appeals and have little
to no pre-existing relationship to the transplant candidate. It
was agreed that the assessment of donor motives becomes
particularly important in evaluating donor suitability. In
addition, these individuals may have less knowledge of the
transplant process and the medical risks that they may face,
compared to individuals who have a longstanding relation-
ship with the transplant candidate. Donor expectations
regarding financial or personal gain also demand careful
consideration in the evaluation and education of these
individuals (Table 2).
PREVENTIVE MEDICINE
The prevalence of renal failure internationally demands a
focus on preventive medical attention that is long overdue.
Straightforward measures such as the detection of hyperten-
sion and the dipstick analysis of the urine in screening clinics
are desperately needed so that cost effective treatments can be
initiated to curtail the development of renal failure. The
nephrologist and the International Society of Nephrology are
central to achieving successful care of this rapidly expanding
population of patients. As Barsoum32 has cogently argued,
‘the obvious task ahead for health authorities in the
developing world is to detect and treat kidney disease at
the earliest possible stage.
In December 2005, representatives from the International
Society of Nephrology, World Heart Federation, International
Diabetes Federation, International Atherosclerosis Federa-
tion, and International Society of Hypertension participated
in a strategic planning workshop in Bellagio, Italy to assess
the rationale and effectiveness of preventive measures for all
the chronic vascular diseases.33
Meanwhile, Mani and the Kidney Help Trust of Chennai
India have been underway for nearly a decade with a program
to prevent chronic renal failure by regular screening of an
entire regional population of 25 000, and by the treatment of
diabetes and hypertension with the least expensive and
available medications.34
This Chennai experience should be a model for all
countries confronted by an expanding population of
diabetics and the elderly. Nearly 60% of the kidney wait list
in the United States is greater than 50 years of age.35 The
WHO estimates that there are 180 million diabetics in the
world and this number is likely to double by 2030. If proper
preventive care is not provided can we anticipate that a
kidney transplant will be readily available as a final measure
of care?36
CONCLUSION
It is now evident that the annual number of available
deceased donors will not resolve the ongoing organ
shortage. Further, the significant mortality that occurs
for those patients awaiting an organ transplant necessitates
the consideration of every possibility of live organ donation.
Nevertheless, the needs of transplant recipients however,
do not outweigh the priority of the long-term health of
organ donors. Concern for donor health, defined in the
broadest sense from both a medical and psychological
perspective, is a pivotal ethical consideration when
physicians subject healthy individuals to a procedure that
has medical risks.
It may be unrealistic to consider live donor kidney
transplantation as the solution to an international public
health epidemic of renal failure that is the result of an aging
population of patients that have had inadequate preventive
medical care.
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